MTOR and neoplasm: Subsequent studies have illustrated that CD8+ T cells, upon activation through IFI35 expressed by tumor cells, stimulate the PI3K/AKT/mTOR pathway, which enhances cell proliferation and the production of cytotoxic effector molecules, thereby augmenting the immune-mediated cytotoxicity against tumor cells.